Literature DB >> 10901381

Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT).

N R Monks1, J A Calvete, N J Curtin, D C Blakey, S J East, D R Newell.   

Abstract

ZD2767P, a nitrogen mustard glutamate prodrug, is currently being evaluated in Phase 1 clinical trials of antibody directed enzyme prodrug therapy (ADEPT). There was no significant relationship between basal glutathione (GSH) concentration and sensitivity to ZD2767P + carboxpeptidase G2 (CPG2) in colorectal tumour cell-lines. Depletion of intracellular GSH using buthionine sulfoximine (BSO) resulted in only a modest potentiation of ZD2767P + CPG2 activity and hence BSO is unlikely to markedly enhance the activity of this ADEPT treatment.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10901381      PMCID： PMC2363482          DOI： 10.1054/bjoc.2000.1240

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  10 in total

Review 1.  Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies.

Authors:  A G Hall; M J Tilby
Journal:  Blood Rev       Date:  1992-09       Impact factor: 8.250

Review 2.  Molecular mechanisms of drug resistance.

Authors:  J D Hayes; C R Wolf
Journal:  Biochem J       Date:  1990-12-01       Impact factor: 3.857

3.  Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT).

Authors:  C J Springer; R Dowell; P J Burke; E Hadley; D H Davis; D C Blakey; R G Melton; I Niculescu-Duvaz
Journal:  J Med Chem       Date:  1995-12-22       Impact factor: 7.446

4.  In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain.

Authors:  T R Chen
Journal:  Exp Cell Res       Date:  1977-02       Impact factor: 3.905

5.  ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumor regressions in colorectal tumor xenografts.

Authors:  D C Blakey; P J Burke; D H Davies; R I Dowell; S J East; K P Eckersley; J E Fitton; J McDaid; R G Melton; I A Niculescu-Duvaz; P E Pinder; S K Sharma; A F Wright; C J Springer
Journal:  Cancer Res       Date:  1996-07-15       Impact factor: 12.701

Review 6.  Compartmentation of glutathione: implications for the study of toxicity and disease.

Authors:  C V Smith; D P Jones; T M Guenthner; L H Lash; B H Lauterburg
Journal:  Toxicol Appl Pharmacol       Date:  1996-09       Impact factor: 4.219

7.  New colorimetric cytotoxicity assay for anticancer-drug screening.

Authors:  P Skehan; R Storeng; D Scudiero; A Monks; J McMahon; D Vistica; J T Warren; H Bokesch; S Kenney; M R Boyd
Journal:  J Natl Cancer Inst       Date:  1990-07-04       Impact factor: 13.506

8.  Methodologies for the application of monobromobimane to the simultaneous analysis of soluble and protein thiol components of biological systems.

Authors:  I A Cotgreave; P Moldéus
Journal:  J Biochem Biophys Methods       Date:  1986-11

9.  Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan.

Authors:  H S Friedman; M E Dolan; S H Kaufmann; O M Colvin; O W Griffith; R C Moschel; S C Schold; D D Bigner; F Ali-Osman
Journal:  Cancer Res       Date:  1994-07-01       Impact factor: 12.701

10.  Nitrogen mustard-DNA interaction in melphalan-resistant mammary carcinoma cells with elevated intracellular glutathione and glutathione-S-transferase activity.

Authors:  M A Alaoui-Jamali; L Panasci; G M Centurioni; R Schecter; S Lehnert; G Batist
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.